TeamDrive
RUS

RusnanoMedInvest

www.rmi.com.ru

RusnanoMedInvest (a subsidiary of RUSNANO) - was founded in March 2012 and is Russia’s and Eastern Europe’s largest venture capital company specializing in innovative developments in the field of pharmaceuticals and biotechnology. Initial funding - $ 380 mln.

The key strategic objective of RusnanoMedInvest is to create a Russian-domiciled locus of world-class expertise in venture capital fundraising, deal origination and execution in Life Sciences, with a clear focus on innovative pharmaceutical projects backed by sustainable, cutting edge technologies.

Together with U.S. life sciences venture firm Domain Associates LLC, RusnanoMedInvest is now executing a pharmaceutical project to assume not less than 20 innovative molecules to be localized in Russia. Ultimately this will significantly reduce the introduction lead time of new and innovative medicines and medical devices in Russia targeted at delivering significant therapeutic benefits and efficiencies in disease areas that are classified as socially significant complex, poorly treated and widely prevalent diseases in Russia  in cases where no domestically sourced, effective treatment methods are available today.

Media Center

  • 24 May 2018

    State Duma adopted a bill to simplify registration of drugs

    It will be possible to register drugs that have the same international nonproprietary names, but different trade names, and being manufactured at the same site. The corresponding government bill No. 327290-7 on amendments to the Federal Law “On Circulation of Medicines” was adopted by the State Duma in the third reading.

  • 23 May 2018

    Today’s realities in the development of local and contract manufacturing

    The representatives of pharmaceutical companies met at the forum of the Adam Smith Institute where they shared their views on the development of local and contract manufacturing. Victor Dmitriev, General Director of the Association of Russian Pharmaceutical Manufacturers, said that Russian manufacturers continue to consider the quality of their products as the most important issue.

  • 23 May 2018

    Russian Ministry included the Kirov region biotech cluster in its register

    The Ministry of Industry and Trade of Russia confirmed that the industrial biotechnology cluster of the Kirov region and its specialized organization “The Association of Industrial Biotechnology Cluster” comply with the requirements approved by the Decree of the Russian Government No. 779, dated July 31, 2016.

  • 22 May 2018

    Russian pharmaceutical market: stability in unstable environment

    According to DSM Group, in 2017, the Russian market was worth 1629 billion rubles, which 8% higher than in 2016. For the first time in three years, the market grew in dollar- and euro-denominated terms. In physical terms, the market growth is similar to the dynamics in value terms. Therefore, the factor of higher prices played virtually no role in expanding the market volume. In 2017, the main driver was the increase in the actual consumption of medicinal products, i.e., the growth in terms of sold packages.

Read more